Loading
A phase 1 trial of LAE118 run by Laekna Limited, not yet recruiting.
A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07787520 by Laekna Limited, with 150 participants planned, started 2026-08, primary completion expected 2029-03. Conditions recorded: Patients With Advanced Solid Tumors. Interventions recorded: LAE118, Fulvestrant, Palbociclib.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/